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the occurrence of intramuscular adipocytes are urgently needed. Here, we show that fibroblast growth
factor-2 (FGF-2) not only stimulates muscle growth but also promotes intramuscular adipogenesis. Using
multiple screening assays upstream and downstream of microRNA (miR)-29a signaling, we located the
secreted protein and adipogenic inhibitor SPARC to an FGF-2 signaling pathway that is conserved
between skeletal muscle cells from mice and humans and that is activated in skeletal muscle of aged
mice and humans. FGF-2 induces the miR-29a/SPARC axis through transcriptional activation of FRA-
1, which binds and activates an evolutionary conserved AP-1 site element proximal in the miR-29a
promoter. Genetic deletions in muscle cells and adeno-associated virus-mediated overexpression of FGF-
2 or SPARC in mouse skeletal muscle revealed that this axis regulates differentiation of fibro/adipogenic
progenitors in vitro and intramuscular adipose tissue (IMAT) formation in vivo. Skeletal muscle from
human donors aged >75 y versus <55 y showed activation of FGF-2-dependent signaling and increased
IMAT. Thus, our data highlights a disparate role of FGF-2 in adult skeletal muscle and reveals a pathway
to combat fat accumulation in aged human skeletal muscle.
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Aged skeletal muscle is markedly affected by fatty muscle infiltra-
tion, and strategies to reduce the occurrence of intramuscular
adipocytes are urgently needed. Here, we show that fibroblast
growth factor-2 (FGF-2) not only stimulates muscle growth but
also promotes intramuscular adipogenesis. Using multiple screen-
ing assays upstream and downstream of microRNA (miR)-29a sig-
naling, we located the secreted protein and adipogenic inhibitor
SPARC to an FGF-2 signaling pathway that is conserved between
skeletal muscle cells from mice and humans and that is activated in
skeletal muscle of aged mice and humans. FGF-2 induces the miR-
29a/SPARC axis through transcriptional activation of FRA-1, which
binds and activates an evolutionary conserved AP-1 site element
proximal in the miR-29a promoter. Genetic deletions in muscle
cells and adeno-associated virus–mediated overexpression of
FGF-2 or SPARC in mouse skeletal muscle revealed that this axis
regulates differentiation of fibro/adipogenic progenitors in vitro
and intramuscular adipose tissue (IMAT) formation in vivo. Skele-
tal muscle from human donors aged >75 y versus <55 y showed
activation of FGF-2–dependent signaling and increased IMAT.
Thus, our data highlights a disparate role of FGF-2 in adult skeletal
muscle and reveals a pathway to combat fat accumulation in aged
human skeletal muscle.
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Skeletal muscle is a fundamental organ for the health of thehuman body (1). It comprises 40% of whole-body mass and
ensures movement, posture, and stability. Moreover, skeletal
muscle participates in heat production and whole-body metabo-
lism. Decreased glucose uptake in muscle tissue promotes de novo
lipogenesis in the liver (2) while the capacity of skeletal muscle to
oxidize fatty acids determines weight gain and obesity (3). The
activation of skeletal muscle during exercise can have beneficial
effects on sympathetic activity and inflammation (4) as well as on
the secretion of myokines into the blood stream (5). Strategies to
maintain muscle mass and function are therefore pivotal to pre-
vent morbidity in the population.
Aging, obesity, and muscle disuse pose a major threat to muscle
health in the society. Starting at 40 y of age, muscle mass declines
by 8% per decade (6). Although this process is variable, in older
adults, the loss of muscle mass can decline more than 2 SDs below
the mean of young healthy adults. This drastic decrease in muscle
mass is defined as sarcopenia and is a key contributor to adverse
events in the elderly such as falls, disability, and death, which are
summarized under the term frailty (7). Once muscle mass de-
creases, a decline of the basal metabolic rate follows. The conse-
quence is an increasing prevalence of obesity, skeletal muscle
insulin resistance, and type 2 diabetes mellitus in the group of
people aged 65 or older (8, 9).
The molecular mechanisms that contribute to the decrease in
skeletal muscle mass during aging and type 2 diabetes are complex
and still incompletely understood. However, a unique feature of
muscle during aging, obesity, and type 2 diabetes is the appearance
of adipose tissue between skeletal muscle fibers, the intramuscular
adipose tissue (IMAT) (10–12). In overweight subjects (body mass
index between 28 and 30 kg/m2), the amount of IMAT can be
substantial and is estimated to relate to 5% (women) or 10%
(men) of whole-body adipose tissue (11). IMAT is generally as-
sociated with systemic insulin resistance (11, 13), decreased
muscle strength (14), and, in older adults, impaired mobility
(15–17). A large body of work over the last years have addressed
the origin of IMAT. Skeletal muscle contains preadipocyte
progenitors termed fibro/adipogenic progenitors (FAPs) that
normally do not form adipocytes but proliferate during muscle
injury to support the commitment of myogenic progenitor cells
(MPs) during muscle repair (18). However, under the conditions
outlined above, rather than undergoing apoptosis, FAPs differ-
entiate to adipocytes and give rise to IMAT (18–20). The mo-
lecular cues that trigger this pathogenesis are unknown and
warrant further investigation.
Here, we expose the fickle role of FGF-2, which participates not
only in the growth of myogenic progenitors and fibers but also
supports the differentiation of FAPs. By following upstream and
downstream signaling events of a master regulator of myogenesis,
microRNA (miR)-29a (21), we identified an intricate FGF-2 sig-
naling pathway in muscle cells, which enhances differentiation of
FAPs in vitro and promotes IMAT formation in vivo during
muscle regeneration via the suppression of the myokine SPARC.
Additionally, the FGF-2/miR-29a/SPARC pathway is enhanced in
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aged skeletal muscle of mice and humans. Our findings reveal an
unexpected side of FGF-2 action that could provide new strategies
to prevent IMAT formation in the aged skeletal muscle.
Results
SPARC Is a Conserved Target of miR-29a in Skeletal Muscle. We have
previously shown that miR-29a is a master regulator of muscle
cell differentiation in vitro (21) and muscle regeneration in vivo
(22). Interestingly, the inhibition of miR-29a in the muscle cell
line C2C12 affected adipogenic differentiation of 3T3 cells in a
coculture system (Fig. 1A). To understand how the inhibition of
miR-29a in muscle cells decreases adipogenic differentiation, we
embarked on identifying secreted targets of miR-29a that par-
ticipate in crosstalk between skeletal muscle and adipocytes. We
used both trancriptomics and proteomics datasets in which miR-
29a was down-regulated in human primary myoblasts and C2C12
myotubes, respectively. We have previously published an RNA
deep sequencing dataset of human myotubes (21), which we now
reanalyzed specifically for miR-29a targets. For the proteomics
dataset, liquid chromatography–mass spectrometry (LC-MS/MS)
was performed on the supernatants of C2C12 myotubes. Suc-
cessful silencing of miR-29a was confirmed using a right shift in
the cumulative distribution fractions plots of the predicted miR-
29a target genes compared to nontargets (SI Appendix, Fig. S1 A
and B) as well as by using enrichment plot analysis (SI Appendix,
Fig. S1 C and D) in both experimental conditions. The silencing of
miR-29a during the differentiation of human myoblasts signifi-






































































































RNA-seq: antagomir-29a vs. ctrl
SPARC





















































































LC-MS/MS: antagomir-29a vs. ctrl
SPARC





















Fig. 1. SPARC is regulated by miR-29a in skeletal muscle both in vitro and in vivo. (A) Coculture of C2C12 myotubes, transfected with antagomir negative
control (NC) or antagomir-29a and 3T3-L1 cells. No coculture control shows 3T3-L1 cells cultured without C2C12 myotubes. Representative images show lipid
droplet (Bodipy; green) and nuclei (Hoechst; blue) staining of 3T3-L1 cells on day 8 after induction of adipogenesis. Lipid area was normalized to nuclei (n = 3).
(Scale bar, 5 mm, Top; 100 μm, Bottom.) (B and C) Volcano plots (significance versus log2 FC) of significantly altered (B) genes (n = 3; FC > |2| and P < 0.05) or
(C) proteins (n = 4; FC > |1| and P < 0.05) after inhibition of miR-29a; n.s. = not significant. (D–F) Sparc expression in (D) C2C12 myotubes (n = 6), (E) mouse
primary myotubes (n = 7), and (F) human primary myotubes (n = 7) after inhibition or overexpression of miR-29a. qPCR values were normalized to 18S ri-
bosomal RNA (rRNA) and plotted relative to negative control antagomir or mimic. (G) Levels of secreted SPARC in conditioned medium from C2C12 myotubes
after inhibition or overexpression of miR-29a as assessed by enzyme-linked immunosorbent assay (n = 6). SPARC levels are plotted relative to negative control
antagomir or mimic. (H and J) miR-29a and (I and K) Sparc expression in ACTA1-Cre miR-29afl/fl versus miR-29afl/fl (n = 5) or Pax7-Cre miR-29afl/fl versus miR-
29afl/fl mice (n = 7). qPCR values were normalized to 18S rRNA (Sparc) or snoRNA234 (miR-29a). Data in A and D–K are plotted as mean ± SEM. Significance was
evaluated by (A) one-way ANOVA with Tukey’s multiple comparisons test, (B and C) differential expression statistic (Benjamini–Hochberg adjusted P value),
and (D–K) two-tailed unpaired Student’s t test. *P ≤ 0.05 **P ≤ 0.01; ***P ≤ 0.001.
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with a P value < 0.05, while the silencing of miR-29a in myotubes
significantly increased the abundance of 79 proteins and decreased
54 proteins (P < 0.05) in the supernatant. To enrich for secreted
proteins with potential functions in crosstalk, LC-MS/MS data
were filtered for direct targets of miR-29a-3p using TargetScan
v7.2, while proteins providing structural support were excluded (10
proteins, annotated as Extracellular Matrix Component; Gene
Ontology term 0044420). The secreted myokine (23) and miR-29a
target (24) Secreted protein acidic and rich in cysteine (SPARC)
was the most significantly up-regulated gene and protein in both
the transcriptomic and proteomic datasets (Fig. 1 B and C). SI
Appendix, Table S1 provides a full list of the significantly changed
proteins and their potential role in adipogenesis. We used three
strategies to provide evidence that SPARC is a direct target of
miR29a in skeletal muscle. First, in vitro, enhanced, or repressed
SPARC levels in response to treatments with miR-29a antagomirs
or mimics was detected at the messenger RNA (mRNA) level and
as secreted protein in C2C12 myotube cultures (Fig. 1 D andG) as
well as at the mRNA level and as secreted protein in primary
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Fig. 2. miR-29a promotes adipogenesis via down-regulation of SPARC in vitro. (A) Sparc expression in wild-type (wt) or C2C12 myoblasts with deleted miR-
29a recognition elements (C2C12 SparcΔMRE) after inhibition of miR-29a (n = 4). qPCR values were normalized to 18S ribosomal RNA (rRNA). (B) Levels of
secreted SPARC in conditioned medium from wt or C2C12 myoblasts with deleted miR-29a recognition elements (C2C12 SparcΔMRE) as assessed by enzyme-
linked immunosorbent assay (n = 4). (C) Cell proliferation in wt or C2C12 cells with deleted miR-29a recognition elements (C2C12 SparcΔMRE) after inhibition of
miR-29a (n = 4). (D and E) Coculture of wt or C2C12 myotubes with deleted miR-29a recognition elements (C2C12 SparcΔMRE) and (D) 3T3-L1 (n = 4) or (E) FAPs
(n = 4). No coculture control shows 3T3-L1 cells or FAPs cultured without C2C12 myotubes. Representative images show lipid droplet (Bodipy; green) and
nuclei (Hoechst; blue) staining of 3T3-L1 or FAPs on day 8 after induction of adipogenesis. Lipid area was normalized to nuclei. (Scale bar, 5 mm, Top; 100 μm,
Bottom.) (F–I) Adipogenic and lipogenic gene expression of (F and G) 3T3-L1 cells or (H and I) FAPs cocultured with C2C12 Sparcwt or C2C12 SparcΔMRE
myotubes on day 8 after induction of adipogenesis (n = 4). No coculture control shows 3T3-L1 cells or FAPs cultured without C2C12 myotubes. qPCR values
were normalized to 18S rRNA. All data are plotted as mean ± SEM. Significance was evaluated by (A and C–I) one-way ANOVA with Tukey’s multiple
comparisons test and (B) two-tailed unpaired Student’s t test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Appendix, Fig. S1 E and F). Second, in vivo, we used two knockout
models of miR-29a in the adult skeletal muscle of mice: ACTA1-
Cre-miR-29afl/fl, which achieved 50% depletion of the miRNA
(Fig. 1H), and Pax7-Cre-miR-29afl/fl, in which miR-29a was de-
pleted by 70% (Fig. 1J). Only miR-29a depletion by 70% resulted
in increased Sparc expression in adult skeletal muscle, indicating a
miRNA target gene threshold requiring >50% knockdown of miR-
29a (Fig. 1 I and K). Third, to prove that SPARC is indeed a direct
target of miR-29a, we deleted two predicted and conserved binding
sites for miR-29a in the 3′ untranslated region (UTR) of SPARC.
The deletion of these sites relieved the miR-29a–dependent re-
pression in reporter gene assays (SI Appendix, Fig. S1 G and H).
Together, our results identify Sparc as a conserved regulated target
of miR-29a in skeletal muscle both in vitro and in vivo. Therefore,
we hypothesized that the inhibition of miR-29a in muscle cells
leads to the up-regulation and subsequent secretion of SPARC,
resulting in the suppression of adipogenic differentiation in the
coculture system.
The miR-29a/SPARC Axis Regulates Skeletal Muscle Preadipocyte
Differentiation In Vitro. To assess the functional role of SPARC
downstream of miR-29a as a potential modulator of FAP cell fate,
we generated four C2C12 cell lines with genomic deletions of the
miR-29a recognition elements (MRE) in the Sparc 3′ UTR using
CRISPR/Cas9 (SparcΔMRE, SI Appendix, Fig. S2A). The up-
regulation of Sparc at the protein level, where its abundance in
the supernatant of the mutant versus wild-type cells was elevated
by approximately twofold, was mirrored by an almost twofold up-
regulation at the mRNA level, in both myoblasts and myotubes
(Fig. 2 A and B, and SI Appendix, Fig. S2B). Strikingly, the inhi-
bition of miR-29a in the mutant cells did not cause a further in-
crease in SPARC mRNA, proving definitely that SPARC
regulation after miR-29a inhibition is caused directly by miR-29a
binding. The proliferation capacity of C2C12 myoblasts after miR-
29a inhibition was decreased (Fig. 2C), a hallmark of miR-29a
action in muscle cells (22). This phenotype was also present in
the C2C12 SparcΔMRE cells, indicating that Sparc does not par-
ticipate in intrinsic signaling events in muscle cells downstream of
miR-29a (Fig. 2C). To assess if SPARC influences the differen-
tiation capacity of adipocyte progenitors, we cocultured Sparcwt or
SparcΔMRE cell lines with 3T3 cells or FAPs isolated from murine
skeletal muscle (Fig. 2 D–I). SparcΔMRE cells strongly inhibited
the differentiation of both 3T3 preadipocytes as well as FAPs and
reduced adipogenic and lipogenic gene expression in both cell
types as compared to Sparcwt cells. The inhibition of FAPs dif-
ferentiation could be a direct effect of SPARC, at least in part, as
the incubation of FAPs with recombinant SPARC was also able to
reduce the differentiation of FAPs (SI Appendix, Fig. S2 C–E).
Importantly, SPARC elevation did not change the fibrogenic,
osteogenic, or smooth muscle programs in FAPs (SI Appendix, Fig.
S2 F–H). Reducing Sparc levels in C2C12 cells during the cocul-
ture experiments using endoribonuclease-prepared small inter-
fering RNA (esiRNA) increased adipocyte differentiation at
baseline and in the presence of antagomir-29a (SI Appendix, Fig.
S2I). Moreover, reducing Sparc levels prevented the inhibitory
effect of antagomir-29a on adipocyte differentiation. Importantly,
the effect of antagomir-29a on 3T3 cell differentiation and
esiRNA against Sparc on FAPs differentiation is not limited to
C2C12 cells but can also be observed in primary muscle cells from
mice and humans (SI Appendix, Fig. S2 J–S). Together, these re-
sults indicate that the miR-29a/SPARC axis is a regulator of adi-
pocyte differentiation that mediates the crosstalks between muscle
cells and preadipocytes residing in adult skeletal muscle.
An FGF-2/MEK1/2/MAPK Signaling Axis Regulates Sparc via miR-29a.
Since miR-29a regulates FAP cell fate, we decided to decipher the
regulatory pathway upstream of this pivotal miRNA. Among
several growth factors and hormonally relevant cues for skeletal
muscle, only FGF-2 was able to induce miR-29a in C2C12 myo-
tubes (Fig. 3A), in line with our previous published observations
that miR-29a/b1 is the highest regulated miRNA cluster by FGF-2
in primary human myoblasts (22). A total of 24 h posttreatment,
FGF-2 induced a dose-dependent up-regulation of miR-29a (SI
Appendix, Fig. S3 A and B) and a reciprocal down-regulation of
SPARC transcript (Fig. 3B). Strikingly, FGF-2–mediated inhibi-
tion of Sparc was abolished in the C2C12 SparcΔMRE cell lines,
implicating that FGF-2, miR-29a, and SPARC belong to the same
signaling pathway (Fig. 3C). To identify signaling events down-
stream of FGF-2 that mediate miR-29a expression, we cloned
1,867 base pairs (bp) of the published miR-29a promoter (25) into
a luciferase reporter vector. Promoter activation by FGF-2 was
localized to a 590-bp fragment (Fig. 3D and SI Appendix, Fig.
S3C), which was used in subsequent experiments with chemical
inhibitors to numerous intracellular pathways downstream of
FGF-2 (26). Overall, we silenced the FGF-2 receptor (PD173074),
RAS-MAPK signaling (PD184352, targeting MEK1/2; NSC23766,
targeting Rac GTPase), PI3K-AKT signaling (LY294002, target-
ing PI3Kα/δ/β), PLC-γ signaling (U73122), and STAT signaling
(Nifuroxazide) in the presence of FGF-2. Notably, the suppression
of FGF-2–activated miR-29a promoter activity was mostly de-
pendent on the inhibition of MAPK/ERK kinase 1/2 (MEK1/2)
(Fig. 3E), which was mimicked by the overexpression of a domi-
nant active form of MEK2 (Fig. 3F). While the PD inhibitor sig-
nificantly reduced the promoter activity also in the absence of
FGF-2, U73122 had no effect alone (SI Appendix, Fig. S3D). In
primary myotubes, FGF-2 treatment increased the phosphoryla-
tion of p44/42 MAPK, the downstream target of MEK1/2
(Fig. 3G). Additionally, in both myoblasts and myotubes from
both mice and humans, MEK1/2 inhibition also prevented the
FGF-2–mediated induction of miR-29a (Fig. 3 H–J and SI Ap-
pendix, Fig. S3 E and F) and increased expression of the miR-29a
target Sparc (Fig. 3 K–M and SI Appendix, Fig. S3 G and H).
Interestingly, MEK1/2 inhibition also affected miR-29a levels and
Sparc expression in the absence of FGF-2. However, the effect
size was much smaller as compared to the regulation in the
presence of FGF-2 and might indicate endogenous activation of
the FGF-2 signaling pathway in muscle cells. Together, these re-
sults establish that MEK1/2 acts upon the miR-29a promoter and
relegates Sparc to a pathway involving FGF-2 signaling via MEK1/
2, p44/42 MAPK, and miR-29a.
The Transcription Factor FRA-1 is Up-Regulated by FGF-2 to Induce
miR-29a Expression. To identify all participants in the signal trans-
duction cascade that determines the expression of miR-29a and
Sparc, we pursued the identity of the transcription factor (TF) that
mediates the effect of FGF-2/MEK1/2 on the miR-29a promoter.
We further narrowed down the promoter region (Fig. 4A) and
identified a 97-bp promoter fragment (−374 to −278 bp upstream
of the transcription start site) that preserved its dependence on
MEK1/2 inhibition and MEK2 stimulation (Fig. 4 B and C). Since
the fragment −374 to −312 did not show promoter activity, we
focused on a 54-nucleotide (nt) promoter region located at −331
to −278 bp. Bioinformatic analysis revealed 55 potential cis-
regulatory elements in this region with 12 TF-binding sites show-
ing a relative match score >0.9. We performed site-directed mu-
tagenesis to sequentially abolish TF binding on the 54-nt promoter
region within the 97-bp fragment and identified a conserved
Fos–Jun consensus site, which is bound by members of the acti-
vating protein-1 (AP-1) family of TFs and responsive to FGF-2
stimulation (Fig. 4 D and E). The mutation of this site successfully
prevented MEK2-stimulated increase of promoter activity com-
pared to the wild-type promoter fragment (Fig. 4F). DNA-binding
activity of the AP-1 family is modulated via phosphorylation and
through its homo- or heterodimer composition, which is deter-
mined by differential expression of the AP-1 protein members Jun,
Fos, activating TF (ATF), and musculoaponeurotic fibrosarcoma
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(MAF) (27). Among the Fos/Jun family members, Fos-related
antigen 1 (Fosl1, encodes protein FRA-1) gene expression was
strongly induced by FGF-2 and markedly down-regulated by
MEK1/2 inhibition (Fig. 4G). Overexpression of the Fosl1 gene in
C2C12 cells and primary mouse myoblasts activated the miR-29a
promoter in the absence of FGF-2 (Fig. 4 H–J), and the knock-
down of Fosl1 prevented the FGF-2–stimulated increase in miR-
29a promoter activity (Fig. 4K). Adeno-associated virus (AAV)-
mediated overexpression of Fosl1 induced miR-29a expression
(Fig. 4 L and M), and the knockdown of Fosl1 prevented the in-
duction of miR-29a expression by FGF-2 (Fig. 4O). Finally, in
cultured human myoblasts, FGF-2 treatment significantly increased
phosphorylation of FRA-1 (SI Appendix, Fig. S4). Chromatin im-
munoprecipitation (ChIP) analysis successfully demonstrated that
phosphorylated FRA-1 occupies the promoter of miR-29a in
human myoblasts. This relationship is significantly increased by
fivefold in the presence of FGF-2 (Fig. 4P). Together, our results
define an FGF-2/FRA-1/miR-29a/SPARC axis that is conserved in
skeletal muscle cells from mice and humans.
Aged Mice Have Higher Levels of the TF p-FRA-1. Next, we wanted to
understand whether the FGF-2 signaling pathway that we identi-
fied in vitro is also active in skeletal muscle in vivo. Since FGF-2
abundance is increased in skeletal muscle during aging in mice
(28, 29), we turned to 25-mo-old aged mice and compared them to
two-mo-old mice (young control). Indeed, aged mice had a higher
expression of Fgf2, Fosl1, and miR-29a (Fig. 5 A–C). Importantly,
Sparc expression and circulating SPARC levels were also lower in
the aged mice (Fig. 5 D and E). Moreover, we successfully dem-
onstrated that aged skeletal muscle is characterized by higher
A B C D
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Fig. 3. FGF-2 signaling decreases Sparc via MEK1/2, p42/44 MAPK, and miR-29a. (A) miR-29a expression in C2C12 myotubes after treatment with respective
recombinant proteins or dexamethasone (n = 7). qPCR values were normalized to snoRNA234. (B and C) Sparc expression in (B) C2C12 myotubes (n = 4) or in
(C) wild-type and C2C12 myoblasts with deleted miR-29a recognition elements (C2C12 SparcΔMRE; n = 4) after treatment with recombinant FGF-2. qPCR values
were normalized to 18S ribosomal RNA (rRNA). (D) miR-29a promoter activity for full-length (−1,493/+195) and truncated (−977/+195, −396/+195) promoter
constructs after treatment with recombinant FGF-2 (n = 6). (E) miR-29a promoter activity for truncated (−396/+195) promoter construct after treatment with
inhibitors against FGFR1 (PD173074), MEK1/2 (PD184352), Rac GTPase (NSC23766), PI3Kα/δ/β (LY294002), STAT1/3/5 (Nifuroxazide), PLC (U73122), and
recombinant FGF-2. Stars indicate significant difference compared to dimethyl sulfoxide control treated with FGF-2 (n = 8). (F) miR-29a promoter activity for
truncated (−396/+195) promoter construct after treatment with recombinant FGF-2 or overexpression of MEK2 (MKK2) (n = 8). Experiments in D–F were
performed in C2C12 myotubes and assessed by normalized luciferase assays. (G) Immunoblot depicting phosphorylation of p44/42 MAPK in C2C12 myotubes
treated with recombinant FGF-2 (n = 6). Band densities were quantified and normalized to total p44/42 MAPK. (H–J) miR-29a and (K–M) Sparc expression in (H
and K) C2C12 myotubes, (I and L) mouse primary myotubes, and (J and M) human primary myotubes after treatment with recombinant FGF-2 and inhibition
of MEK1/2 signaling (PD184352; n = 6). qPCR values were normalized to snoRNA234 (miR-29a) or 18S rRNA (Sparc). All data are plotted as mean ± SEM.
Significance was evaluated by (A, C–F, and H–M) one-way ANOVA with (A and E) Dunnett’s or (C, D, F, and H–M) Tukey’s multiple comparisons test and (B and
G) two-tailed unpaired Student’s t test. n.s. = not significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Fig. 4. The TF FRA-1 mediates miR-29a expression downstream of FGF-2. (A) miR-29a promoter activity for truncated promoter constructs as indicated and
treatment with recombinant FGF-2 (n = 6). (B and C) miR-29a promoter activity for truncated promoter construct (−374/−278) after treatment with
recombinant FGF-2 and (B) inhibition (n = 6) or (C) activation (n = 8) of MEK1/2 signaling (MKK2). (D) miR-29a promoter activity for truncated wild type (wt) or
mutated (M1, M2, M3) promoter constructs after treatment with recombinant FGF-2 (n = 6). Respective mutageneses abolished binding of indicated tran-
scription factors located either on a sense (+) or antisense (−) strand. Cis-regulatory elements are given in relation to transcription start site. (E) Depicted are
wt and mutated (M1, M2, M3) miR-29a promoter sequences used in D and F. Mutated nucleotides are shown in gray letters. Motif analysis revealed a
conserved Fos–Jun-binding site removed in mutant 3 (M3). Stars indicate identical nucleotides among species. (F) miR-29a promoter activity for truncated wt
(−374/−278) or mutated (M3) promoter constructs after activation of MEK2 signaling (MKK2; n = 6). (G) Gene expression of indicated AP-1 transcription
factors in C2C12 myotubes after treatment with recombinant FGF-2 and inhibition of MEK1/2 signaling (n = 6). (H) Fosl1 expression in C2C12 myoblasts after
overexpression of Fosl1 (n = 6). (I and J) miR-29a promoter activity for truncated promoter construct (−374/278) after treatment with recombinant FGF-2 and/
or overexpression of Fosl1, performed in (I) C2C12 myoblasts or (J) mouse primary myoblasts (n = 6). (K) miR-29a promoter activity for truncated promoter
construct (−374/−278) after treatment with recombinant FGF-2 and/or knockdown of Fosl1 (n = 5). (L and M) L Fosl1 and M miR-29a expression in mouse
primary myotubes after AAV-mediated overexpression of Fosl1 (n = 6). (N) Fosl1 expression in mouse primary myoblasts after knockdown of Fosl1 (n = 5). (O)
miR-29a expression in mouse primary myoblasts after treatment with recombinant FGF-2 and knockdown of Fosl1 (n = 3). (P) ChIP of p-FRA1 on miR-29a
promoter performed in human primary myoblasts after treatment with recombinant FGF-2 (n = 4). miR-29a promoter enrichment was assessed relative to
total input DNA by qPCR and is depicted in relation to negative control (IgG). Representative samples were visualized on an agarose gel (Left). Data in A–D, F,
and K were performed in C2C12 myotubes and assessed by normalized luciferase assays. qPCR values in G, H, and L–O were normalized to snoRNA234 (miR-
29a) or 18S rRNA. All data are plotted as mean ± SEM. Significance was evaluated by (A–D, F, I–K, O, and P) one-way ANOVA with Tukey’s multiple com-
parisons test, (G) two-way ANOVA with Tukey’s multiple comparisons test, and (H and L–N) two-tailed unpaired Student’s t test. n.s. = not significant; *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001.
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levels of phosphorylated FRA-1 and that FRA-1 binding to the
miR-29a promoter is significantly increased in aged versus young
mice as revealed by ChIP analysis (Fig. 5 F and G). Importantly,
FAPs isolated from aged mice retained a similar sensitivity to
SPARC-induced inhibition of adipogenesis as compared to FAPs
isolated from young mice (SI Appendix, Fig. S5), indicating that
the decreased Sparc levels that we observed in skeletal muscle
from aged mice could be relevant for the FAPs. We conclude that
the FGF-2/FRA-1/miR-29a/SPARC axis is consistently regulated
in vivo in aged skeletal muscle of mice and could affect aging-
related IMAT.
FGF-2 and SPARC Regulate IMAT Formation. To demonstrate the
function of the FGF-2 /SPARC axis as a regulator of adipocyte
differentiation in vivo, we employed the glycerol model of muscle
regeneration in which fatty infiltration can be readily observed (20)
as opposed to other mouse models such as denervation atrophy
(30–33) or cancer cachexia (34–37). To this end, we injected Fgf2
or Sparc-overexpressing AAV 9 directly into the tibialis anterior
muscle of mice as previously described (38–42). This approach is
expected to infect both type 1 and type 2 fibers but not adult
muscle stem cells (42). After 3 wk, muscle regeneration and fatty
infiltration was induced using a single glycerol injection, and 2 wk
later, muscles were analyzed for adipocyte infiltration (Fig. 6A).
AAV-Fgf2 induced Fgf2 expression and increased muscle mass
(Fig. 6 B and C). Importantly, IMAT formation was drastically
induced in paraffin sections from AAV-Fgf2 compared to AAV-
GFP–injected muscle where IMAT area and total adipocyte
number were significantly increased by 12-fold and ninefold, re-
spectively (Fig. 6F). Accordingly, at the molecular level, fatty
acid–binding protein 4 (Fabp4) and peroxisome proliferator–
activated receptor gamma (Pparg) were significantly up-regulated
(Fig. 6D and E). Strikingly, overexpression of Sparc using the same
AAV approach (Fig. 6G) led to the opposite effect. IMAT for-
mation and total adipocyte number were significantly decreased by
more than 50% with the AAV-Sparc versus AAV-GFP virus
(Fig. 6J). This decrease in adipocyte infiltration was accompanied
by a significant decrease in the expression of adipocyte markers
Fabp4 and Pparg (Fig. 6 H and I). Interestingly, FAPs numbers
changed in the same direction as IMAT after the introduction of
both AAV-Fgf2 or AAV-Sparc (SI Appendix, Fig. S6 A–F), but
these effects were more subtle and unlikely explain the pronounced
effects that we observed for IMAT formation. We conclude that
the FGF-2/SPARC axis regulates the differentiation of FAPs
in vitro and IMAT formation in vivo (see Fig. 7). Importantly,
AAV-Sparc also reduced IMAT in aged mice (SI Appendix, Fig.
S6 G–J), providing further support for the role of FGF-2/SPARC
in aging-related IMAT.
FGF-2–Dependent Signaling Is Activated in Aged Human Skeletal
Muscle. Lastly, we asked whether the FGF-2–dependent signal-
ing pathway that regulates SPARC is also activated in aged skel-
etal muscle from humans (patient characteristics in SI Appendix).
Similarly to aged skeletal muscle from mice, in aged human
muscle, the expression of miR-29a was significantly up-regulated,
while its target gene SPARC was significantly down-regulated as
compared to young human muscle (Fig. 8 C and D). While the up-
regulation of FGF2 and FOSL1 did not reach statistical signifi-
cance (Fig. 8 A and B), FGF-2 expression in skeletal muscle
positively correlated with age and FOSL1 levels (Fig. 8 G and H).
Compared to young controls, IMAT infiltration in aged human
skeletal muscle was significantly increased by fourfold in paraffin
sections (Fig. 8I), and the expression of the adipocyte marker
FABP4 was significantly induced (Fig. 8E). Together, our results
provide evidence that the FGF-2–dependent signaling pathway
that causes the induction of miR-29a and the down-regulation of
SPARC is conserved between mice and humans and associated
















































































































































Fig. 5. Aged skeletal muscle contains increased p-FRA-1 levels that mediate down-regulation of Sparc by miR-29a. (A) Fgf2, (B) Fosl1, (C) miR-29a, and (D)
Sparc expression in 2-mo-old (young) versus 25-mo-old (aged) mouse tibialis anterior muscle (n = 6). qPCR values were normalized to Tbp or snoRNA234 (miR-
29a). (E) Levels of circulating SPARC levels in young versus aged mice as assessed by enzyme-linked immunosorbent assay (n = 5 versus 4). (F) Immunoblot
depicting phosphorylation of FRA-1 in young versus aged mouse tibialis anterior muscle (n = 4). Band densities were quantified and normalized to GAPDH. (G)
ChIP of p-FRA1 on miR-29a promoter performed in young versus aged mouse gastrocnemius muscle (n = 6). miR-29a promoter enrichment was assessed
relative to total input DNA by qPCR and is depicted in relation to negative control (IgG). Representative samples were visualized on an agarose gel (Left). All
data are plotted as mean ± SEM. Significance was evaluated by (A–F) two-tailed unpaired Student’s t test and (G) one-way ANOVA with Tukey’s multiple
comparisons test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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FGF-2 is a critical growth factor for myogenic progenitor cells
(MPs) in the adult muscle stem cell niche. Here, we report the link
between FGF-2 and IMAT formation. Our results reveal two
opposing roles of FGF-2 with beneficial or adverse effects in
skeletal muscle, the stimulation of muscle growth on the one hand
and the increase in IMAT on the other. Targeting the adipogenic
axis of FGF-2 signaling could ameliorate function and prevent
adverse outcomes associated with the aged skeletal muscle.
FGF-2 signaling in human skeletal muscle is poorly understood
(43). Our data provide insights into the effects of aging on FGF-2.
We show that FGF-2 expression in human skeletal muscle posi-
tively correlates with aging and that aging affects miR-29a and
SPARC expression, two signaling molecules downstream of FGF-
2. In muscle, FGF-2 is secreted by both MPs (44) and adult
myofibers (28, 45) onto the extracellular matrix of skeletal muscle
(46) and predominantly affects the proliferation of MPs. In fact,
the inhibition of FGF-2 signaling induced differentiation of MPs
and decreased muscle mass (47). In addition, FGF-2 might pro-
mote vessel formation (48) since FGF-2 gene delivery to excisional
muscle wounds enhanced not only the formation of regenerating
myotubes but also angiogenesis (49). Our results identify FAPs as
a third population of cells that benefit from FGF-2 during
muscle injury. The role of FGF-2 signaling during adipogenesis
in classical fat depots has produced conflicting results. FGF-2
enhances adipogenesis in mesenchymal stem cells (50). Additionally,
the activation of p44/42 MAPK signaling initiates differentiation
in preadipocytes (51), although the phosphorylation of PPAR-γ by
MAPK prevents the final maturation of adipocytes (52). FGF-2
inhibited adipogenesis of human bone marrow stromal cells (53),
and the disruption of FGF-2 activated the adipogenic program in
mesenchymal marrow stromal cells (54). The differential effects of
FGF-2 for classical WAT might reflect a concentration-dependent
biphasic effect (55).
We have identified SPARC as the link between FGF-2 and
IMAT formation in skeletal muscle. We use multiple strategies to
demonstrate that SPARC is a direct target of miR-29a and that
this relationship is conserved across species. SPARC expression is
enhanced when FGF-2/MEK1/2 signaling is inhibited in both
murine and human primary muscle cells. Furthermore, genomic
mutations in the SPARC 3′ UTR abolish FGF-2 as well as miR-
29a–mediated repression, increase SPARC secretion, and inhibit
FAPs differentiation in coculture systems. Our results are in line
with the role of SPARC in the classical white adipose depot in
which SPARC participates in the inhibition of white adipocyte
differentiation (56–58). Sparc-null mice have larger subcutanous
and larger epidydimal fat pads (56). SPARC is a matrix-associated
glycoprotein that elicits changes in cell shape, inhibits cell-cycle
progression, and influences the synthesis of extracellular matrix
(56, 59). The mechanisms of SPARC involving adipogenesis in-
clude remodeling the extracellular matrix by enhancing the depo-





















































































































































































































































































Fig. 6. FGF-2 and SPARC are regulators of IMAT formation. (A) Experimental overview of intramuscular (i.m.) AAV9 injections. (B) Relative tissue weight and
(C) Fgf2, (D) Fabp4, and (E) Pparg expression in AAV-Fgf2–infected tibialis anterior muscle 2 wk after glycerol injection (n = 7 versus 6). qPCR values were
normalized to 18S ribosomal RNA (rRNA). (F and J) IMAT formation in representative hematoxylin and eosin staining of transverse sections in (F) AAV-Fgf2–
(n = 7 versus 6) or (J) AAV-Sparc– (n = 4 versus 5) infected tibialis anterior muscle 2 wk after glycerol injection and analysis of relative IMAT area and adipocyte
count. (Scale bar, 0.5 mm, Top; 100 μm, Bottom.) (G) Sparc, (H) Fabp4, and (I) Pparg expression in AAV-Sparc–infected tibialis anterior muscle 2 wk after
glycerol injection (n = 6 versus 6 versus 5). qPCR values were normalized to 18S rRNA. All data are plotted as mean ± SEM. Significance was evaluated by (B–F
and J) two-tailed unpaired Student’s t test and (G–I) one-way ANOVA with Tukey’s multiple comparisons test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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or inhibition of laminin expression and its α6-integrin receptor
(57). Moreover, SPARC has been shown to promote the accu-
mulation of β-catenin (57), which inhibits PPAR-γ activity (60).
Interestingly, exercise stimulates SPARC expression in skeletal
muscle from human and mice (23). Our data might therefore
have clinical implications for strategies to prevent IMAT for-
mation, for example, the design of exercise protocols that aim to
maximize SPARC levels in muscle tissue. Mild exercise or higher
intensity exercise has already been shown to increase SPARC
expression in skeletal muscle in elderly individuals (61, 62).
While the effects of SPARC on IMAT are striking, less is known
about the effects of SPARC on muscle regeneration. After the
overexpression of SPARC in skeletal muscle, we noted a small
decrease in fiber number and shift to smaller fiber diameters (SI
Appendix, Fig. S7 A–C), but the significance of these effects
needs further investigation.
It is also important to note that not only mature myofibers but
also MPs and other cell types could be an important source for
SPARC in skeletal muscle. We interpret the lack of effect on
Sparc mRNA in whole-muscle lysates in the Acta1-CreER model
as a result of not reaching a biological threshold for the regu-
lation of Sparc by miR-29a in myofibers. However, an alternative
explanation could be that in the constitutive Pax7-Cre model, the
deletion of miR-29a in MPs contributes to the increase in Sparc.
Tissue panels confirm that miR-29a and Sparc are also expressed
in MPs and FAPs (SI Appendix, Fig. S7 D and E) but to a lesser
extent compared to whole-muscle tissue. In addition, we have
previously reported that miR-29a represents 0.1% of all miR-
NAs in MPs but 0.75% of all miRNAs in tibialis anterior muscle
(24, 63). These data would support the hypothesis of a miR-29a
threshold for Sparc regulation in mature myofibers. In any case,
regardless of the potential sources for Sparc, the up-regulation of
Sparc in the Pax7-Cre model demonstrates that the myogenic
lineage is an important contributor for Sparc expression in
skeletal muscle.
Aging is associated with a decline in the number of MPs (64)
and a loss of their ability to retain a quiescent state (28). Myofibers
are the principal source of FGF-2 for the satellite cell niche.
Rampant FGF-2 expression in murine myofibers implicates them
as the main contributors to stem cell depletion during aging (28,
29). The reason for the increased FGF-2 in aged skeletal muscle is
not known but might reflect a failed attempt to repair the aged
muscle. Indeed, the activation of FGF/p38 MAPK has been
demonstrated in aged satellite cells (65). Furthermore, FGF-2
target genes p21 and p16 are more epigenetically silenced in
young versus old stem cells (29). FGF signaling is complex and
depends on the availability of not only FGF-2 but also of cor-
eceptors and components of the extracellular matrix such as
syndecan-4, β1-integrin, and fibronectin (26, 65). Also, dynamic
changes in the sulfation levels of heparin sulfate increased FGF-2
signaling in aged skeletal muscle (66). The identification of precise
FGF-2 signaling events in aged skeletal muscle in our study should
aid in the accurate estimation of FGF-2 signaling capacity not only
during aging but also in other clinically relevant pathologies such
as obesity or muscle atrophy in which FGF-2 signaling events have
not been reported yet. A pronounced tissue heterogeneity might
provide limitations for using a bulk analysis of FGF-2 signaling in
muscle samples in vivo. While AAV-Fgf2 induced miR-29a and
reduced Sparc levels as expected in primary myotubes in vitro (SI
Appendix, Fig. S7 F–I), we did not observe the same correlations in
our muscle samples at day 35 after AAV-Fgf2 injection (SI Ap-
pendix, Fig. S7 J–L). The massive fatty infiltration might require a
better spatial resolution of gene expression analysis. Indeed, miR-
29a and Sparc levels differ between muscle tissue and classical
white adipose depots (SI Appendix, Fig. S7 M and N), while their
expression in intramuscular adipocytes is still unknown.
Through classical promoter analysis experiments and bio-
informatics, we identified the AP-1–binding site on the miR-29a
promoter and the TF FRA-1 as effector. FRA-1 is the TF which
responds to FGF-2 as well as MEK1/2 treatments. Manipulations
of FGF-2/MEK1/2 resulted in regulations of FRA-1 and miR-29a.
Our results provide an insight into the role of AP-1 in adult skeletal
muscle. Previous studies focused on its role during muscle cell
differentiation in which c-jun and MyoD can coordinate muscle
enhancer factors (67), and AP-1 sites might share putative common
target genes with MEF2 (68). The expression of FRA-1 is reduced
during C2C12 differentiation (68) in line with the decrease in miR-
29a expression (22). A role for AP-1 in adult skeletal muscle is
supported by findings that the expression of AP-1 members in
human skeletal muscle increases after exercise, with the highest
regulation observed for FOSL1 (69). Furthermore, in a mouse
model for muscle atrophy, FRA-1 binding to the MMP-2 promoter
increased fourfold (70). Our results indicate that FRA-1 could be
an important component of the response of skeletal muscle
during aging.
Undifferentiated proliferating FAPs are necessary for successful
muscle regeneration (71). Accordingly, FAPs cannot simply be
erased to prevent IMAT. Therefore, strategies are needed that
can modulate the fate of FAPs and their propensity to differen-
tiate to adipocytes in disease states. The extracellular matrix
(ECM) seems to be an important mediator of the cell fate of
FAPs. In a mouse model of limb girdle muscular dystrophy 2B, the
progressive accumulation of annexin A2 in the myofiber ECM
promoted FAP differentiation into adipocytes, while a lack of
annexin A2 prevented FAP adipogenesis (72). Additionally, the
type 2 innate immune system has also been shown to regulate
FAPs. Il4/Il13 secretion from eosinophils can activate the prolif-
eration of FAPs, and injections of Il4 during glycerol-induced
muscle regeneration reduced the formation of adipocytes (73).
Targeting the fate of FAPs seems to be a promising strategy to
Fig. 7. An FGF-2 signaling pathway promotes intramuscular adipogenesis in
the aged skeletal muscle. Binding of fibroblast growth factor-2 (FGF-2)
phosphorylates the intracellular tyrosine kinase domain of fibroblast growth
factor receptor (FGFR), which activates intracellular signaling pathways in-
cluding MAPK/ERK kinase 1/2 (MEK1/2) to phosphorylate extracellular signal-
regulated kinases (ERK1/2; p44/42 MAPK). MAPK activity increases both the
abundance of Fosl1 and transactivating capacities of the Fos–Jun hetero-
dimer. Phosphorylation of Fos-related antigen (FRA-1) enhances its binding
to the activator protein-1 (AP-1) DNA-binding site located in the miR-29a
promoter to stimulate transcription. In the aged skeletal muscle, enhanced
FGF-2 signaling increases phosphorylated FRA-1 levels, which in turn pro-
mote miR-29a expression. Enhanced miR-29a levels stimulate differentiation
of FAPs into adipocytes via the reduction of SPARC, promoting IMAT
formation.
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prevent IMAT formation. Secreted factors such as SPARC
therefore represent important therapeutic targets.
To date, the regulation of IMAT formation is poorly under-
stood. Linking growth factor signaling pathways to the pleiotropic
effects of miRNAs to myokine secretion and FAP differentiation
has the potential to provide novel diagnostic and therapeutic ap-
proaches. Early detection of an increased risk for IMAT based on
the FGF-2/FRA-1/miR-29a/SPARC axis and its use to improve
fatty muscle degeneration could help to prevent IMAT and its
sequelae, loss of muscle mass, and function in the older population.
Materials and Methods
Details of human patients and the full procedures for animal experiments, cell
preparation, fluorescence-activated cell sorting, cell culture, RNA extraction,
complementary DNA synthesis, qRT-PCR, proliferation assay, enzyme-linked
immunosorbent assay, plasmid construction, luciferase assay, CRISPR-Cas9
genome editing, AAV production, ChIP, protein extraction, Western blot,
histology, LC-MS/MS, RNA sequencing, bioinformatics, and statistical analysis
are provided in SI Appendix.
Data Availability.We declare that all data supporting the findings of this study
are available within the article and its SI Appendix and have been deposited in
Dryad (DOI: 10.5061/dryad.j6q573nf6) (74). The RNA sequencing data de-
scribed in this report have been deposited in the Gene Expression Omnibus
database (GSE154254) (75). The mass spectrometry proteomics data have been
deposited to the ProteomeXchange consortium via the Proteomics Identifi-
cations Database (PRIDE) partner repository with the dataset identifier
PXD020575 (76).
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Fig. 8. Aged human skeletal muscle shows decreased SPARC levels and increased IMAT formation. (A) FGF2, (B) FOSL1, (C) miR-29a, (D) SPARC, (E) FABP4, and
(F) PPARG expression in young (<55 y; n = 5) versus aged (>75 y; n = 6) Tensor fasciae latae muscle. qPCR values were normalized to 18S ribosomal RNA or U6
small nuclear RNA (miR-29a). (G and H) Pearson correlation and linear regression line between (G) age versus FGF2 mRNA expression and (H) FGF2 versus
FOSL1 mRNA expression in Tensor fasciae latae muscle of young and aged donors (n = 11). (I) IMAT formation in representative hematoxylin and eosin
stainings of transverse sections from young versus aged Tensor fasciae latae muscle. Intramuscular adipocytes are indicated by red arrowheads. (Scale bar, 200
μm.) Relative IMAT area was quantified in two consecutive sections obtained from two different areas per donor (n = 5). All data are plotted as mean ± SEM.
Significance was evaluated by (A–F and I) two-tailed unpaired Student’s t test and (G and H) Pearson correlation coefficients. *P ≤ 0.05.
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